Bastiaan Sallevelt

93 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.2. Continued. STOPP Action Clarity rating n=80 F4 Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 mg/ day, ferrous gluconate> 1800 mg/day; 50% G3 Anti-muscarinic bronchodilators (e.g. ipratropium, tiotropium) 50% J1 Sulphonylureas with a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) 50% J2 Thiazolidenediones (e.g. rosiglitazone, pioglitazone) 50% K4 Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon 50% E2 Direct thrombin inhibitors (e.g. dabigatran) 58% E3 Factor Xa inhibitors (e.g. rivaroxaban, apixaban) 58% F2 PPI 58% H8 NSAID 58% B3 Beta-blocker 67% B4 Beta blocker 67% B6 Loop diuretic 67% B7 Loop diuretic 67% B8 Thiazide diuretic 67% B9 Loop diuretic 67% B11 ACE inhibitors or Angiotensin Receptor Blockers 67% C3 Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors 67% C6 Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% C8 Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% C9 Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% C10 NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% C11 NSAID 67% D1 Tricyclic Antidepressants (TCAs) 67% D2 Initiation of Tricyclic Antidepressants (TCAs) 67% D4 Selective serotonin re-uptake inhibitors (SSRI’s) 67% 2

RkJQdWJsaXNoZXIy MTk4NDMw